Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK2 | Q9H0K1 | 16/20 | 0.50 |
| ▸ | SIK3 | Q9Y2K2 | 9/20 | 0.41 |
| ▸ | SIK1 | P57059 | 8/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593330 | 0.92 | SIK2 (0.58) | SIK2SIK3SIK1CYP2C9CYP2C19 | |
| SCHEMBL21593487 | 0.85 | SIK2 (0.48) | SIK2SIK3SIK1CYP2C9CYP2C19 | |
| SCHEMBL26438239 | 0.84 | SIK2 (0.46) | SIK2SIK3SIK1CYP2C9CYP2C19 | |
| SCHEMBL21593303 | 0.82 | SIK2 (0.44) | SIK2SIK3SIK1CYP2C9CYP2C19 | |
| SCHEMBL32691523 | 0.82 | SIK2 (0.44) | SIK2SIK3SIK1CYP2C9CYP2C19 | |
| SCHEMBL26439513 | 0.79 | SIK2 (0.41) | SIK2SIK3SIK1CYP2C9CYP2C19 | |
| SCHEMBL21593383 | 0.78 | SIK2 (0.41) | SIK2SIK3SIK1CYP2C9CYP2C19 | |
| SCHEMBL26439618 | 0.78 | SIK2 (0.41) | SIK2SIK3SIK1CYP2C9CYP2C19 | |
| SCHEMBL32691269 | 0.78 | SIK2 (0.41) | SIK2SIK3SIK1CYP2C9CYP2C19 | |
| SCHEMBL24169269 | 0.77 | SIK2 (0.58) | SIK2SIK3SIK1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2025-04-01 | — | — | US | disclosed |
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402911-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1A, TNF, IL6 | SIK2 4381/4885SIK3 3390/4885SIK1 3905/4885 |
| US-12264156-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | TNF, IL1A, COL1A1 | SIK2 4373/4885SIK3 3341/4885SIK1 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.